FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022676942> ?p ?o ?g. }

• W2022676942 endingPage "1211" @default.
• W2022676942 startingPage "1203" @default.
• W2022676942 abstract "Introduction:Malignant pleural mesothelioma (MM) is an aggressive asbestos-associated malignancy with limited therapeutic options. This study describes the overexpression of Ephrin B2 receptor (EPHB2) in MM cell lines and tumors, and the effect of its manipulation on proliferative and invasive qualities of the disease.Methods:Using expression arrays, we investigated EPHB2 in MM tumors compared with normal mesothelium. EPHB2 and downstream target expression were evaluated using reverse-transcriptase polymerase chain reaction and immunoblotting methods. The biological significance of EPHB2 in MM was evaluated using in vitro functional assays with and without targeting by EPHB2-short hairpin RNA or blocking peptide in two mesothelioma cell lines, HP-1 and H2595.Results:EPHB2 is overexpressed in all MM cell lines, but not in benign mesothelial cells, and is significantly elevated in MM tumor tissue compared with matched normal peritoneum. Targeted knockdown of EPHB2 in HP-1 and H2595 cell lines reduced its expression and that of EPHB2 downstream targets such as matrix metalloproteinase (MMP-2) and vascular endothelial growth factor, whereas caspase 2 and caspase 8 had increased expression. Inhibition of EPHB2 resulted in a significant decrease in scratch closure (1.25-fold–1.8-fold), proliferation (1.5-fold), and invasion (1.7-fold–1.8-fold) compared with the controls. Most notably, however, EPHB2 silencing resulted in a significant increase in apoptotic proteins and activity.Conclusion:EPHB2 seems to play an important role in MM pathogenesis and these findings indicate that EPHB2 could serve as a potential novel therapeutic target for treatment of the disease. Malignant pleural mesothelioma (MM) is an aggressive asbestos-associated malignancy with limited therapeutic options. This study describes the overexpression of Ephrin B2 receptor (EPHB2) in MM cell lines and tumors, and the effect of its manipulation on proliferative and invasive qualities of the disease. Using expression arrays, we investigated EPHB2 in MM tumors compared with normal mesothelium. EPHB2 and downstream target expression were evaluated using reverse-transcriptase polymerase chain reaction and immunoblotting methods. The biological significance of EPHB2 in MM was evaluated using in vitro functional assays with and without targeting by EPHB2-short hairpin RNA or blocking peptide in two mesothelioma cell lines, HP-1 and H2595. EPHB2 is overexpressed in all MM cell lines, but not in benign mesothelial cells, and is significantly elevated in MM tumor tissue compared with matched normal peritoneum. Targeted knockdown of EPHB2 in HP-1 and H2595 cell lines reduced its expression and that of EPHB2 downstream targets such as matrix metalloproteinase (MMP-2) and vascular endothelial growth factor, whereas caspase 2 and caspase 8 had increased expression. Inhibition of EPHB2 resulted in a significant decrease in scratch closure (1.25-fold–1.8-fold), proliferation (1.5-fold), and invasion (1.7-fold–1.8-fold) compared with the controls. Most notably, however, EPHB2 silencing resulted in a significant increase in apoptotic proteins and activity. EPHB2 seems to play an important role in MM pathogenesis and these findings indicate that EPHB2 could serve as a potential novel therapeutic target for treatment of the disease." @default.
• W2022676942 created "2016-06-24" @default.
• W2022676942 creator A5022127360 @default.
• W2022676942 creator A5031503507 @default.
• W2022676942 creator A5041428040 @default.
• W2022676942 creator A5052394856 @default.
• W2022676942 creator A5069852856 @default.
• W2022676942 creator A5089386096 @default.
• W2022676942 date "2013-09-01" @default.
• W2022676942 modified "2023-09-27" @default.
• W2022676942 title "Overexpression of EPH Receptor B2 in Malignant Mesothelioma Correlates with Oncogenic Behavior" @default.
• W2022676942 cites W1506304328 @default.
• W2022676942 cites W1574807134 @default.
• W2022676942 cites W1584018958 @default.
• W2022676942 cites W1586806649 @default.
• W2022676942 cites W1942214720 @default.
• W2022676942 cites W1970217079 @default.
• W2022676942 cites W1971056168 @default.
• W2022676942 cites W1973180811 @default.
• W2022676942 cites W1974384115 @default.
• W2022676942 cites W1976310806 @default.
• W2022676942 cites W1979842763 @default.
• W2022676942 cites W1980969730 @default.
• W2022676942 cites W1983763042 @default.
• W2022676942 cites W1992187858 @default.
• W2022676942 cites W1992212640 @default.
• W2022676942 cites W1996131261 @default.
• W2022676942 cites W1997208169 @default.
• W2022676942 cites W2001954506 @default.
• W2022676942 cites W2018224223 @default.
• W2022676942 cites W2024156824 @default.
• W2022676942 cites W2038894508 @default.
• W2022676942 cites W2042409437 @default.
• W2022676942 cites W2042646467 @default.
• W2022676942 cites W2045901576 @default.
• W2022676942 cites W2047523756 @default.
• W2022676942 cites W2047694154 @default.
• W2022676942 cites W2049543624 @default.
• W2022676942 cites W2049547244 @default.
• W2022676942 cites W2071946945 @default.
• W2022676942 cites W2073028327 @default.
• W2022676942 cites W2077304999 @default.
• W2022676942 cites W2078638255 @default.
• W2022676942 cites W2081508876 @default.
• W2022676942 cites W2090282518 @default.
• W2022676942 cites W2093842873 @default.
• W2022676942 cites W2095824051 @default.
• W2022676942 cites W2101737157 @default.
• W2022676942 cites W2105912939 @default.
• W2022676942 cites W2115916707 @default.
• W2022676942 cites W2122388238 @default.
• W2022676942 cites W2123467604 @default.
• W2022676942 cites W2135456387 @default.
• W2022676942 cites W2140861361 @default.
• W2022676942 cites W2155473026 @default.
• W2022676942 cites W2162876548 @default.
• W2022676942 cites W2170210185 @default.
• W2022676942 cites W259489194 @default.
• W2022676942 doi "https://doi.org/10.1097/jto.0b013e31829ceb6a" @default.
• W2022676942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23887168" @default.
• W2022676942 hasPublicationYear "2013" @default.
• W2022676942 type Work @default.
• W2022676942 sameAs 2022676942 @default.
• W2022676942 citedByCount "15" @default.
• W2022676942 countsByYear W20226769422014 @default.
• W2022676942 countsByYear W20226769422015 @default.
• W2022676942 countsByYear W20226769422016 @default.
• W2022676942 countsByYear W20226769422017 @default.
• W2022676942 countsByYear W20226769422019 @default.
• W2022676942 countsByYear W20226769422020 @default.
• W2022676942 countsByYear W20226769422021 @default.
• W2022676942 countsByYear W20226769422022 @default.
• W2022676942 crossrefType "journal-article" @default.
• W2022676942 hasAuthorship W2022676942A5022127360 @default.
• W2022676942 hasAuthorship W2022676942A5031503507 @default.
• W2022676942 hasAuthorship W2022676942A5041428040 @default.
• W2022676942 hasAuthorship W2022676942A5052394856 @default.
• W2022676942 hasAuthorship W2022676942A5069852856 @default.
• W2022676942 hasAuthorship W2022676942A5089386096 @default.
• W2022676942 hasBestOaLocation W20226769421 @default.
• W2022676942 hasConcept C101544691 @default.
• W2022676942 hasConcept C12519072 @default.
• W2022676942 hasConcept C126322002 @default.
• W2022676942 hasConcept C142724271 @default.
• W2022676942 hasConcept C170286479 @default.
• W2022676942 hasConcept C170493617 @default.
• W2022676942 hasConcept C173396325 @default.
• W2022676942 hasConcept C190283241 @default.
• W2022676942 hasConcept C19331615 @default.
• W2022676942 hasConcept C2777407522 @default.
• W2022676942 hasConcept C2779747549 @default.
• W2022676942 hasConcept C2780942790 @default.
• W2022676942 hasConcept C2909640154 @default.
• W2022676942 hasConcept C31573885 @default.
• W2022676942 hasConcept C48297814 @default.
• W2022676942 hasConcept C502942594 @default.
• W2022676942 hasConcept C54355233 @default.
• W2022676942 hasConcept C55493867 @default.

• next